FSD Pharma

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Aphria

HEXO Corp

Akerna Corp

Philip Morris

SNDL Inc.

Tilray Brands

22nd Century Group

cbdMD Inc

Pyxus International Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in 2021.

These 10 Pot Stocks Smoked the Last Week of April

Toronto, Ontario--(Newsfile Corp. - April 26, 2021) - On Monday, April 26, 2021, the group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) (the "Company" or "FSD") filed and mailed an information circular and gold proxy to FSD's shareholders for the upcoming annual general and special meeting of FSD to be held on May 14, 2021 (the "Meeting"). The Concerned Shareholders are urging FSD shareholders to help...

Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders' Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy

TORONTO--(BUSINESS WIRE)---- $HUGE--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") announces the filing of its Management Information Circular (the "Circular") and an accompanying letter to shareholders related to the Annual & Special Meeting scheduled for May 14, 2021, copies of which are available under the Company's SEDAR profile. FSD Pharma is at a critical turning point, and the outcome of this proxy contest will greatly affect the future of shareholders' investments in

FSD Pharma Files Proxy Materials and Sends Letter to Shareholders

Focused on lead anti-inflammatory drug FSD-201 Launched Phase 2 study of drug known as micro PEA in December 2020 Developing drugs to treat gastrointestinal diseases in dogs and cats What FSD Pharma does: FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) is a publicly-traded holding company that owns subsidiary FSD Pharma BioSciences Inc, a specialty biotech pharmaceutical R&D firm focused on developing multiple applications of its lead anti-inflammatory drug FSD-201. The drug is now one of several therapeutics being advanced that could help reduce severe and deadly lung infection in coronavirus (COVID-19) patients.

FSD Pharma throws resources behind legacy anti-inflammatory drug as potential coronavirus therapy

Canopy Growth

Greenlane Holdings

Innovative Industrial Properties

OrganiGram Holdings Inc.

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

These 9 Cannabis Stocks Caught Fire This Week

TORONTO, April 5, 2021 /PRNewswire/ - On Tuesday, March 30, 2021, Anthony Durkacz, a founding director and member of the group of concerned shareholders, which also includes founding shareholder Zeeshan Saeed, (the "Concerned Shareholders") of FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (the "Company" or "FSD") received a Notice of Appeal from FSD (the "Appeal") of the March 5, 2021 decision (the "Decision") of the Ontario Superior Court of Justice (Commercial List) (the "Court"). The Decision, which resulted from an application to the Court brought by Mr.

FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting

Corbus Pharmaceuticals Holdings

Intec Parent

The Week Where New York Legalizes Recreational Marijuana

TORONTO--(BUSINESS WIRE)---- $HUGE #FSD--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced that it has commenced an application in the Ontario Superior Court seeking orders from the Court about the conduct of FSD's annual general and special meeting of shareholders currently scheduled for May 14, 2021 (the "Annual Meeting"). The Notice of Application arises from a proxy solicitation that a group led by Mr. Zeeshan Saeed (a former director) and Mr. Anthony Durkacz (a cu

FSD Pharma Commences Proceedings Against Dissident Shareholders

FSD Pharma is a biopharmaceutical research company specializing in medical applications of cannabinoids. The company found a possible treatment for COVID-19 and is attempting a Phase II study.

FSD Pharma Pivots From Cannabis To COVID-19 Treatment

bluebird bio

Immatics NV

Onconova Therapeutics

bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's session.

Why Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving Wednesday

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) has entered into a license agreement with Innovet Italia SRL to develop US Food and Drug Administration-approved veterinary drugs for the treatment of gastrointestinal diseases in dogs and cats.  Under the agreement, Innovet granted the company a license to use ultramicronized-palmitoylethanolamide (ultramicronized PEA or ultra-micro PEA) to develop the drugs.

FSD Pharma in license agreement with Innovet Italia to develop FDA-approved drugs to treat gastrointestinal diseases in dogs and cats

HUGE stock is on the move Wednesday after FSD Pharma announced a potentially lucrative move in the pet care market. Here's what to know.

HUGE Stock: Why Pet Care Play FSD Pharma Is Soaring Today

The stock price of FSD Pharma Inc (NYSE: HUGE) has increased by over 50% pre-market. This is why it happened.

HUGE Stock Price Increases Over 50% Pre-Market: Why It Happened

TORONTO--(BUSINESS WIRE)---- $HUGE--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces that it has entered into a license agreement (the “License Agreement”) with Innovet Italia S.R.L. (“Innovet”), under which Innovet granted the Company a license to use ultramicronized-palmitoylethanolamide (or ultramicronized PEA) (“ultra-micro PEA”) to develop U.S. Food and Drug Administration (“FDA”) approved veterinary drugs for the treatment of gastro-intestinal diseases in C

FSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats

Toronto, Ontario--(Newsfile Corp. - March 8, 2021) - The group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) (the "Company" or "FSD") which includes two founding directors, Anthony Durkacz and Zeeshan Saeed, are pleased to announce that they were successful in their request that the Ontario Superior Court of Justice (Commercial List) (the "Court") order the Company to accelerate the date of its previously called annual shareholders'...

Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Issued Shares

Aurora Cannabis

Cronos Group

Village Farms International

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will continue to develop in the 2021.

Cannabis Stocks Felt the Reddit Rumble This Week

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) said it has entered into an equity sales agreement with A.G.P./Alliance Global Partners covering the sale of Class B subordinate voting shares of the company on an 'at-the-market' basis.

FSD Pharma signs agreement covering the sale of Class B shares on an 'at-the-market' basis

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that it has entered into an Equity Distribution Agreement dated February 11, 2021 (the "Sales Agreement") with A.G.P./Alliance Global Partners (the "Sales Agent"). Under the Sales Agreement the Company may, at its discretion and from time-to-time during the term of the Sales Agreement, sell, through the Sales Agent, Class B Subordinate Voting Shares of the Company (the "Class B Sha

FSD Pharma Announces US$20M At-The-Market Offering

Arena Pharmaceuticals

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will develop in the 2021.

8 Pot Stocks in Focus Amid the WallStreetBets Frenzy

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces the following corporate updates. Corporate Update The Company continues to pursue its strategy of completing a Phase 2 clinical trial for the use of its lead compound, ultramicronized-palmitoylethanolamide (or ultramicronized PEA) (“FSD201”), to treat hospitalized COVID-19 patients in a double-blind study (the “Study”). The Company is expected to randomize 352 patients with COVID

FSD Provides Corporate Update

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company”) today announced that it will hold its annual meeting of shareholders (the “Meeting”) on June 29, 2021. The Meeting will address normal course matters, including the presentation of the Company's audited financial statements, as well as matters contained in a requisition for a special meeting submitted to the Company by certain shareholders of the Company claiming to hold in excess of 5.1% of the C

FSD Pharma Sets Date for Annual Meeting

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced the dosing of the first patient in its Phase 2a clinical trial of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) for the treatment of hospitalized patients with COVID-19. COVID-19 Trial Design The FSD201 COVID-19 Trial is a randomized, controlled, double-blind, multicenter study, conducted on 352 patients to assess the efficacy and safety of FSD201 dosed a

FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19

Zynerba Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to watch in the upcoming week.

11 Cannabis Stocks Making Moves While Riding the 'Green Wave'

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The filing is available on SEDAR. Financial and corporate highlights include: Completion of financings for gross proceeds of $19.5 million USD through two registered direct offerings. As of September 30, 2020, cash & non-cash assets are $56.2 million CAD and short & long

FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

TORONTO--(BUSINESS WIRE)-- #FSDPharma--FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that, subject to court certification and other customary conditions, it has entered into a definitive settlement agreement (the "Settlement Agreement") with respect to the class action litigation commenced by a plaintiff shareholder in the Ontario Superior Court of Justice in February 2019 relating to the build-out of its facility in Cobourg, Ontario (the "Settled Action"). The Com

FSD Pharma Announces Settlement of Class Action Proceeding

News for FSD Pharma Stock (HUGE)